Purpose: This study was aimed at determining if significant uterine tachysystole was associated with adverse fetal or neonatal outcomes during cervical ripening and induction of labor. Methods: Women undergoing cervical ripening and subsequent labor induction (n = 905) were assessed for tachysystole, defined as ≥6 contractions in each of 2 consecutive 10-minute windows. Women with ≥3 episodes of tachysystole were compared to women with no tachysystole. Results: Over a 5-year period, 70% of the 905 participants (n = 631) had no tachysystole, 143 had 1 or 2 episodes whereas 131 or 15% had ≥3 episodes (p = 0.991). The cesarean delivery rate was lower among those with tachysystole (28.2 vs. 34.1%), but the difference was not significant (p = 0.197). Non-reassuring fetal tracings were more common in the tachysystole group (14.4 vs. 21.4%, p = 0.017), but the Apgar scores at 5 min and the umbilical cord pH and base excess were similar between the 2 groups (p = 0.502, p = 0.435, and p = 0.535, respectively). Conclusions: Tachysystole was not associated with adverse perinatal outcomes when compared to women with no tachysystole during cervical ripening and induction of labor.

1.
Stephenson ML, Powers BL, Wing DA: Fetal heart rate and cardiotocographic abnormalities with varying dose misoprostol vaginal inserts. J Matern Fetal Neonatal Med 2013;26:127-131.
2.
Bakker PC, Kurver PH, Kuik DJ, Van Geijn HP: Elevated uterine activity increases the risk of fetal acidosis at birth. Am J Obstet Gynecol 2007;196:313.e1-e6.
3.
Simpson KR, James DC: Effects of oxytocin-induced uterine hyperstimulation during labor on fetal oxygen status and fetal heart rate patterns. Am J Obstet Gynecol 2008;199:34.e1-e5.
4.
Macones GA, Hankins GD, Spong CY, Hauth J, Moore T: The 2008 national institute of child health and human development workshop report on electronic fetal monitoring. Obstet Gynecol 2008;112:661-666.
5.
Carbone JF, Tuuli MG, Fogertey PJ, Roehl KA, Macones GA: Combination of foley bulb and vaginal misoprostol compared with vaginal misoprostol alone for cervical ripening and labor induction: a randomized controlled trial. Obstet Gynecol 2013;121(2 pt 1):247-252.
6.
American College of Obstetricians and Gynecologists: ACOG practice bulletin no. 106: intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009;114:192-202.
7.
Association of Women's Health Obstetric and Neonatal Nurses (AWHONN). Washington, Consulting and Staff Development, 2010.
8.
Schifrin BS, Deymier P, Cohen WR: Fetal neurological injury related to mechanical forces of labor and delivery; in Zhang L, Longo L (eds): Stress and Development in Health and Disease; Beyond Phenomenology. New York, Nova Biomedical, 2014, pp 651-688.
9.
Stewart RD, Bleich AT, Lo JY, Alexander JM, McIntire DD, Leveno KJ: Defining uterine tachysystole: how much is too much? AM J Obstet Gynecol 2012;207:290.e1-e6.
10.
Smith S, Zacharias J, Lucas V, Warrick PA, Hamilton EF: Clinical associations with uterine tachysystole. J Matern Fetal Neonatal Med 2014;27:709-713.
11.
Barrilleaux PS, Bofill JA, Terrone DA, Magann EF, May WL, Morrison JC: Cervical ripening and induction of labor with misoprostol, dinoprostone gel, and a Foley catheter: a randomized trial of 3 techniques. Am J Obstet Gynecol 2002;186:1124-1129.
12.
Zhang J, Landy HJ, Branch DW, Burkman R, Haberman S, Gregory KD, et al; Consortium on Safe Labor: Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol 2010;116:1281-1287.
13.
Crane JM, Young DC: Meta-analysis of low-dose versus high-dose oxytocin for labour induction. J Soc Obstet Gynaecol Can 1998;20:1215-1223.
14.
Heuser CC, Knight S, Esplin MS, Eller AG, Holmgren CM, Manuck TA, Richards D, Henry E, Jackson GM: Tachysystole in term labor: incidence, risk factors, outcomes, and effect on fetal heart tracings. Am J Obstet Gynecol 2013;209:32.e1-e6.
15.
Klauser CK, Christensen EE, Chauhan SP, Bufkin L, Magann EF, Bofill JA, Morrison JC: Use of fetal pulse oximetry among high-risk women in labor: a randomized clinical trial. Am J Obstet Gynecol 2005;192:1810-1817; discussion 1817-1819.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.